NZ591879A - Detection of mutations in a gene associated with resistance to viral infection, OAS1 - Google Patents
Detection of mutations in a gene associated with resistance to viral infection, OAS1Info
- Publication number
- NZ591879A NZ591879A NZ591879A NZ59187904A NZ591879A NZ 591879 A NZ591879 A NZ 591879A NZ 591879 A NZ591879 A NZ 591879A NZ 59187904 A NZ59187904 A NZ 59187904A NZ 591879 A NZ591879 A NZ 591879A
- Authority
- NZ
- New Zealand
- Prior art keywords
- resistance
- viral infection
- mutations
- oas1
- disclosed
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 230000035772 mutation Effects 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 title 1
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 241000282412 Homo Species 0.000 abstract 1
- 102000003960 Ligases Human genes 0.000 abstract 1
- 108090000364 Ligases Proteins 0.000 abstract 1
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- -1 methods Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ603105A NZ603105A (en) | 2003-10-23 | 2004-10-22 | Detection of mutations in a gene associated with resistance to viral infection, oasi |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51388803P | 2003-10-23 | 2003-10-23 | |
| US54237304P | 2004-02-06 | 2004-02-06 | |
| US55475804P | 2004-03-19 | 2004-03-19 | |
| US56052404P | 2004-04-08 | 2004-04-08 | |
| US57832304P | 2004-06-09 | 2004-06-09 | |
| US58350304P | 2004-06-28 | 2004-06-28 | |
| US60524304P | 2004-08-26 | 2004-08-26 | |
| NZ58016904 | 2004-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ591879A true NZ591879A (en) | 2012-11-30 |
Family
ID=42331514
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ591879A NZ591879A (en) | 2003-10-23 | 2004-10-22 | Detection of mutations in a gene associated with resistance to viral infection, OAS1 |
| NZ603105A NZ603105A (en) | 2003-10-23 | 2004-10-22 | Detection of mutations in a gene associated with resistance to viral infection, oasi |
| NZ580169A NZ580169A (en) | 2003-10-23 | 2004-10-22 | Detection of mutations in a gene associated with resistance to viral infection, OAS1 (SEQ ID NO:48) |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ603105A NZ603105A (en) | 2003-10-23 | 2004-10-22 | Detection of mutations in a gene associated with resistance to viral infection, oasi |
| NZ580169A NZ580169A (en) | 2003-10-23 | 2004-10-22 | Detection of mutations in a gene associated with resistance to viral infection, OAS1 (SEQ ID NO:48) |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20050191649A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2011142913A (cg-RX-API-DMAC7.html) |
| IL (1) | IL175089A (cg-RX-API-DMAC7.html) |
| NZ (3) | NZ591879A (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0415771A (pt) | 2003-10-23 | 2006-12-26 | Illumigen Biosciences Inc | detecção de mutações em um gene associado à resistência a infecção viral, oas1 |
| UA95446C2 (ru) | 2005-05-04 | 2011-08-10 | Іллюміджен Байосайєнсіз, Інк. | Мутаци в генах oas1 |
| US11439689B2 (en) * | 2016-11-14 | 2022-09-13 | Kaohsiung Medical University | Method for detecting whether glucose metabolism is abnormal, and prevention and treatment therefor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863873A (en) * | 1980-01-14 | 1989-09-05 | Esa, Inc. | Method for biological testing and/or developing pharmaceuticals for treatment of disorders |
| US5266459A (en) * | 1992-02-24 | 1993-11-30 | The Scripps Research Institute | Gaucher's disease: detection of a new mutation in intron 2 of the glucocerebrosidase gene |
| US5597709A (en) * | 1994-01-27 | 1997-01-28 | Human Genome Sciences, Inc. | Human growth hormone splice variants hGHV-2(88) and hGHV-3(53) |
| US5840565A (en) * | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
| AU3367799A (en) * | 1998-03-30 | 1999-10-18 | Esa Inc. | Methodology for predicting and/or diagnosing disease |
| US20010034023A1 (en) * | 1999-04-26 | 2001-10-25 | Stanton Vincent P. | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing |
| US20030165921A1 (en) * | 2000-02-03 | 2003-09-04 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| AU2001245619A1 (en) * | 2000-03-09 | 2001-09-17 | Chiron Corporation | Human genes and gene expression products |
| AU2002341207A1 (en) * | 2001-05-08 | 2002-11-18 | Switch Biotech Ag | Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing |
| US6818420B2 (en) * | 2002-02-27 | 2004-11-16 | Biosource International, Inc. | Methods of using FET labeled oligonucleotides that include a 3′-5′ exonuclease resistant quencher domain and compositions for practicing the same |
| US7354908B2 (en) * | 2002-04-30 | 2008-04-08 | University Of South Florida | Materials and methods for prevention and treatment of RNA viral diseases |
| WO2004044124A2 (en) * | 2002-05-17 | 2004-05-27 | Baylor College Of Medicine | Identification of oligoadenylate synthetase-like genes |
-
2004
- 2004-10-22 NZ NZ591879A patent/NZ591879A/xx not_active IP Right Cessation
- 2004-10-22 US US10/972,135 patent/US20050191649A1/en not_active Abandoned
- 2004-10-22 NZ NZ603105A patent/NZ603105A/en not_active IP Right Cessation
- 2004-10-22 NZ NZ580169A patent/NZ580169A/en not_active IP Right Cessation
-
2006
- 2006-04-23 IL IL175089A patent/IL175089A/en not_active IP Right Cessation
-
2011
- 2011-02-03 JP JP2011021746A patent/JP2011142913A/ja not_active Withdrawn
-
2012
- 2012-05-15 JP JP2012111782A patent/JP2012183069A/ja active Pending
-
2013
- 2013-05-07 JP JP2013097618A patent/JP2013208117A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ603105A (en) | 2014-08-29 |
| JP2013208117A (ja) | 2013-10-10 |
| JP2011142913A (ja) | 2011-07-28 |
| IL175089A (en) | 2013-10-31 |
| IL175089A0 (en) | 2006-08-20 |
| US20050191649A1 (en) | 2005-09-01 |
| NZ580169A (en) | 2011-04-29 |
| JP2012183069A (ja) | 2012-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004006838A3 (en) | Novel kinases | |
| WO2001038503A3 (en) | Novel human protein kinases and protein kinase-like enzymes | |
| MXPA04012614A (es) | Xilanasas, acidos nucleicos que las codifican, y metodos para hacerlas y usarlas. | |
| DK0998568T3 (da) | Mutant med uracil phosphoribosyltransferaseaktivitet | |
| AU8881201A (en) | Tnf receptor-like molecules and uses thereof | |
| IL187079A (en) | OligoAdenylate Synthetic Protein 1, Pharmaceutical Preparations Containing and Using It | |
| WO2005040428A3 (en) | Detection of mutations in a gene associated with resistance to viral infection, oas1 | |
| WO2003076561A3 (en) | Recombinase fusion protein with enhanced cellular uptake | |
| WO2001066594A3 (en) | Human protein kinases and protein kinase-like enzymes | |
| GB0418388D0 (en) | Cell therapy | |
| EP1487864A4 (en) | THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES AND METHODS OF USE THEREOF | |
| IL162600A0 (en) | Cc-chemokine mutants as cc-chemokine antagonists | |
| AU2002356534A8 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
| WO2001055356A3 (en) | Human protein kinases and protein kinase-like enzymes | |
| WO1999066051A3 (en) | Nek-related and bub1-related protein kinases | |
| AU2003217956A8 (en) | Therapeutic polypeptides, nucleic acids encoding same and methods of use | |
| WO2005049641A3 (en) | Surface-located campylobacter jejuni polypeptides | |
| HK1052726A1 (zh) | 人类蛋白激酶及类似蛋白激酶的酵素 | |
| EP1401858A4 (en) | THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS COATING THEREOF AND METHOD OF USE | |
| EP1551972A4 (en) | NUCLEIC ACIDS, POLYPEPTIDES, SINGLE NUCLEOTIDE POLYMORPHISMS AND METHOD OF USE THEREOF | |
| WO2007025079A3 (en) | Detection of mutations in a gene associated with resistance to viral infection, oas2 or oas3 | |
| EP1443913A4 (en) | THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES AND METHODS OF USE THEREOF | |
| WO2001088137A3 (en) | Human myd88 adapter-like protein and functional fragments thereof | |
| WO2006004660A3 (en) | Detection of mutations in a gene associated with resistance to viral infection | |
| WO2004006843A3 (en) | Combination therapies with l-fmau for the treatment of hepatitis b virus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: KINETA 2, LLC, US Free format text: OLD OWNER(S): ILLUMIGEN BIOSCIENCES, INC. |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 22 OCT 2014 BY AJ PARK Effective date: 20131007 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 OCT 2015 BY COMPUTER PACKAGES INC Effective date: 20141001 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 OCT 2016 BY COMPUTER PACKAGES INC Effective date: 20151031 |
|
| LAPS | Patent lapsed |